APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuromyelitis Optica Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuromyelitis Optica Therapy Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchNeuromyelitis Optica Therapy Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuromyelitis Optica Therapy Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuromyelitis Optica Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuromyelitis Optica Therapy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuromyelitis Optica Therapy Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuromyelitis Optica Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neuromyelitis Optica Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuromyelitis Optica Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuromyelitis Optica Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuromyelitis Optica Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neuromyelitis Optica Therapy include CBOP, CSL, Fresenius, Grifols, Gyjtrs, Intas, NANG KUANG, Octapharma and Tianjin Kingyork, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neuromyelitis Optica Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuromyelitis Optica Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Neuromyelitis Optica Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuromyelitis Optica Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuromyelitis Optica Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neuromyelitis Optica Therapy revenue, projected growth trends, production technology, application and end-user industry.

Neuromyelitis Optica Therapy Segment by Company

CBOP

CSL

Fresenius

Grifols

Gyjtrs

Intas

NANG KUANG

Octapharma

Tianjin Kingyork

Baxter

Pfizer

Sandoz

Teva

Neuromyelitis Optica Therapy Segment by Type

Glucocorticoids

Immunotherapies

Other

Neuromyelitis Optica Therapy Segment by Application

Acute Attack

Remission Prophylactic Treatment

Neuromyelitis Optica Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neuromyelitis Optica Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neuromyelitis Optica Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Glucocorticoids Major Player Table 3. Immunotherapies Major Player Table 4. Other Major Player Table 5. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Acute Attack Major Player Table 7. Remission Prophylactic Treatment Major Player Table 8. Neuromyelitis Optica Therapy Industry Trends Table 9. Neuromyelitis Optica Therapy Industry Drivers Table 10. Neuromyelitis Optica Therapy Industry Opportunities and Challenges Table 11. Neuromyelitis Optica Therapy Industry Restraints Table 12. Global Neuromyelitis Optica Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Neuromyelitis Optica Therapy Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Neuromyelitis Optica Therapy Market Share by Region (2021-2026) Table 15. Global Neuromyelitis Optica Therapy Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Neuromyelitis Optica Therapy Market Share by Region (2027-2032) Table 17. Global Neuromyelitis Optica Therapy Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Neuromyelitis Optica Therapy Revenue Market Share by Players (2021-2026) Table 19. Global Neuromyelitis Optica Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Neuromyelitis Optica Therapy Key Players Headquarters & Area Served Table 21. Global Neuromyelitis Optica Therapy Players, Product Type & Application Table 22. Global Neuromyelitis Optica Therapy Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Neuromyelitis Optica Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Neuromyelitis Optica Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuromyelitis Optica Therapy Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Neuromyelitis Optica Therapy Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2021-2026) Table 29. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2027-2032) Table 30. Global Neuromyelitis Optica Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neuromyelitis Optica Therapy Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Neuromyelitis Optica Therapy Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2021-2026) Table 34. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2027-2032) Table 35. CBOP Company Information Table 36. CBOP Business Overview Table 37. CBOP Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. CBOP Neuromyelitis Optica Therapy Product Portfolio Table 39. CBOP Recent Development Table 40. CSL Company Information Table 41. CSL Business Overview Table 42. CSL Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. CSL Neuromyelitis Optica Therapy Product Portfolio Table 44. CSL Recent Development Table 45. Fresenius Company Information Table 46. Fresenius Business Overview Table 47. Fresenius Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Fresenius Neuromyelitis Optica Therapy Product Portfolio Table 49. Fresenius Recent Development Table 50. Grifols Company Information Table 51. Grifols Business Overview Table 52. Grifols Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Grifols Neuromyelitis Optica Therapy Product Portfolio Table 54. Grifols Recent Development Table 55. Gyjtrs Company Information Table 56. Gyjtrs Business Overview Table 57. Gyjtrs Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Gyjtrs Neuromyelitis Optica Therapy Product Portfolio Table 59. Gyjtrs Recent Development Table 60. Intas Company Information Table 61. Intas Business Overview Table 62. Intas Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Intas Neuromyelitis Optica Therapy Product Portfolio Table 64. Intas Recent Development Table 65. NANG KUANG Company Information Table 66. NANG KUANG Business Overview Table 67. NANG KUANG Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. NANG KUANG Neuromyelitis Optica Therapy Product Portfolio Table 69. NANG KUANG Recent Development Table 70. Octapharma Company Information Table 71. Octapharma Business Overview Table 72. Octapharma Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Octapharma Neuromyelitis Optica Therapy Product Portfolio Table 74. Octapharma Recent Development Table 75. Tianjin Kingyork Company Information Table 76. Tianjin Kingyork Business Overview Table 77. Tianjin Kingyork Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Tianjin Kingyork Neuromyelitis Optica Therapy Product Portfolio Table 79. Tianjin Kingyork Recent Development Table 80. Baxter Company Information Table 81. Baxter Business Overview Table 82. Baxter Neuromyelitis Optica Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Baxter Neuromyelitis Optica Therapy Product Portfolio Table 84. Baxter Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Neuromyelitis Optica Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pfizer Neuromyelitis Optica Therapy Product Portfolio Table 89. Pfizer Recent Development Table 90. Sandoz Company Information Table 91. Sandoz Business Overview Table 92. Sandoz Neuromyelitis Optica Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sandoz Neuromyelitis Optica Therapy Product Portfolio Table 94. Sandoz Recent Development Table 95. Teva Company Information Table 96. Teva Business Overview Table 97. Teva Neuromyelitis Optica Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Teva Neuromyelitis Optica Therapy Product Portfolio Table 99. Teva Recent Development Table 100. North America Neuromyelitis Optica Therapy Revenue by Type (2021-2026) & (US$ Million) Table 101. North America Neuromyelitis Optica Therapy Revenue by Type (2027-2032) & (US$ Million) Table 102. North America Neuromyelitis Optica Therapy Revenue by Application (2021-2026) & (US$ Million) Table 103. North America Neuromyelitis Optica Therapy Revenue by Application (2027-2032) & (US$ Million) Table 104. North America Neuromyelitis Optica Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. North America Neuromyelitis Optica Therapy Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Neuromyelitis Optica Therapy Revenue by Country (US$ Million) & (2027-2032) Table 107. Europe Neuromyelitis Optica Therapy Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Neuromyelitis Optica Therapy Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Neuromyelitis Optica Therapy Revenue by Application (2021-2026) & (US$ Million) Table 110. Europe Neuromyelitis Optica Therapy Revenue by Application (2027-2032) & (US$ Million) Table 111. Europe Neuromyelitis Optica Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Europe Neuromyelitis Optica Therapy Revenue by Country (2021-2026) & (US$ Million) Table 113. Europe Neuromyelitis Optica Therapy Revenue by Country (US$ Million) & (2027-2032) Table 114. China Neuromyelitis Optica Therapy Revenue by Type (2021-2026) & (US$ Million) Table 115. China Neuromyelitis Optica Therapy Revenue by Type (2027-2032) & (US$ Million) Table 116. China Neuromyelitis Optica Therapy Revenue by Application (2021-2026) & (US$ Million) Table 117. China Neuromyelitis Optica Therapy Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Neuromyelitis Optica Therapy Revenue by Type (2021-2026) & (US$ Million) Table 119. Asia Neuromyelitis Optica Therapy Revenue by Type (2027-2032) & (US$ Million) Table 120. Asia Neuromyelitis Optica Therapy Revenue by Application (2021-2026) & (US$ Million) Table 121. Asia Neuromyelitis Optica Therapy Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Neuromyelitis Optica Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Asia Neuromyelitis Optica Therapy Revenue by Region (US$ Million) & (2021-2026) Table 124. Asia Neuromyelitis Optica Therapy Revenue by Region (US$ Million) & (2027-2032) Table 125. SAMEA Neuromyelitis Optica Therapy Revenue by Type (2021-2026) & (US$ Million) Table 126. SAMEA Neuromyelitis Optica Therapy Revenue by Type (2027-2032) & (US$ Million) Table 127. SAMEA Neuromyelitis Optica Therapy Revenue by Application (2021-2026) & (US$ Million) Table 128. SAMEA Neuromyelitis Optica Therapy Revenue by Application (2027-2032) & (US$ Million) Table 129. SAMEA Neuromyelitis Optica Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. SAMEA Neuromyelitis Optica Therapy Revenue by Country (2021-2026) & (US$ Million) Table 131. SAMEA Neuromyelitis Optica Therapy Revenue by Country (US$ Million) & (2027-2032) Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Neuromyelitis Optica Therapy Image Figure 2. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuromyelitis Optica Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Glucocorticoids Image Figure 5. Immunotherapies Image Figure 6. Other Image Figure 7. Global Neuromyelitis Optica Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neuromyelitis Optica Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 9. Acute Attack Image Figure 10. Remission Prophylactic Treatment Image Figure 11. Global Neuromyelitis Optica Therapy Market Size (US$ Million) & (2021-2032) Figure 12. Global Neuromyelitis Optica Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Neuromyelitis Optica Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Neuromyelitis Optica Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Neuromyelitis Optica Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neuromyelitis Optica Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2021-2032) Figure 19. Global Neuromyelitis Optica Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2021-2032) Figure 22. North America Neuromyelitis Optica Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032) Figure 24. North America Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032) Figure 25. North America Neuromyelitis Optica Therapy Revenue Share by Country (2021-2032) Figure 26. United States Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Neuromyelitis Optica Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032) Figure 31. Europe Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032) Figure 32. Europe Neuromyelitis Optica Therapy Revenue Share by Country (2021-2032) Figure 33. Germany Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Neuromyelitis Optica Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032) Figure 43. China Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032) Figure 44. Asia Neuromyelitis Optica Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032) Figure 46. Asia Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032) Figure 47. Asia Neuromyelitis Optica Therapy Revenue Share by Region (2021-2032) Figure 48. Japan Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Neuromyelitis Optica Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032) Figure 56. SAMEA Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032) Figure 57. SAMEA Neuromyelitis Optica Therapy Revenue Share by Country (2021-2032) Figure 58. Brazil Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Neuromyelitis Optica Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Glucocorticoids
  • Immunotherapies
  • Other
Applications
  • Acute Attack
  • Remission Prophylactic Treatment
Companies covered
  • CBOP
  • CSL
  • Fresenius
  • Grifols
  • Gyjtrs
  • Intas
  • NANG KUANG
  • Octapharma
  • Tianjin Kingyork
  • Baxter
  • Pfizer
  • Sandoz
  • Teva

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuromyelitis Optica Therapy Market by Type
  3. 1.2.1 Global Neuromyelitis Optica Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Glucocorticoids
  5. 1.2.3 Immunotherapies
  6. 1.2.4 Other
  7. 1.3 Neuromyelitis Optica Therapy Market by Application
  8. 1.3.1 Global Neuromyelitis Optica Therapy Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Acute Attack
  10. 1.3.3 Remission Prophylactic Treatment
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Neuromyelitis Optica Therapy Market Dynamics
  1. 2.1 Neuromyelitis Optica Therapy Industry Trends
  2. 2.2 Neuromyelitis Optica Therapy Industry Drivers
  3. 2.3 Neuromyelitis Optica Therapy Industry Opportunities and Challenges
  4. 2.4 Neuromyelitis Optica Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neuromyelitis Optica Therapy Market Perspective (2021-2032)
  2. 3.2 Global Neuromyelitis Optica Therapy Growth Trends by Region
  3. 3.2.1 Global Neuromyelitis Optica Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuromyelitis Optica Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Neuromyelitis Optica Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neuromyelitis Optica Therapy Revenue by Players
  2. 4.1.1 Global Neuromyelitis Optica Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Neuromyelitis Optica Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neuromyelitis Optica Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuromyelitis Optica Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neuromyelitis Optica Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Neuromyelitis Optica Therapy Players, Product Type & Application
  8. 4.5 Global Neuromyelitis Optica Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neuromyelitis Optica Therapy Market CR5 and HHI
  11. 4.6.3 2025 Neuromyelitis Optica Therapy Tier 1, Tier 2, and Tier 3
5 Neuromyelitis Optica Therapy Market Size by Type
  1. 5.1 Global Neuromyelitis Optica Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuromyelitis Optica Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Neuromyelitis Optica Therapy Revenue Market Share by Type (2021-2032)
6 Neuromyelitis Optica Therapy Market Size by Application
  1. 6.1 Global Neuromyelitis Optica Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neuromyelitis Optica Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Neuromyelitis Optica Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 CBOP
  2. 7.1.1 CBOP Company Information
  3. 7.1.2 CBOP Business Overview
  4. 7.1.3 CBOP Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 CBOP Neuromyelitis Optica Therapy Product Portfolio
  6. 7.1.5 CBOP Recent Developments
  7. 7.2 CSL
  8. 7.2.1 CSL Company Information
  9. 7.2.2 CSL Business Overview
  10. 7.2.3 CSL Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 CSL Neuromyelitis Optica Therapy Product Portfolio
  12. 7.2.5 CSL Recent Developments
  13. 7.3 Fresenius
  14. 7.3.1 Fresenius Company Information
  15. 7.3.2 Fresenius Business Overview
  16. 7.3.3 Fresenius Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Fresenius Neuromyelitis Optica Therapy Product Portfolio
  18. 7.3.5 Fresenius Recent Developments
  19. 7.4 Grifols
  20. 7.4.1 Grifols Company Information
  21. 7.4.2 Grifols Business Overview
  22. 7.4.3 Grifols Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Grifols Neuromyelitis Optica Therapy Product Portfolio
  24. 7.4.5 Grifols Recent Developments
  25. 7.5 Gyjtrs
  26. 7.5.1 Gyjtrs Company Information
  27. 7.5.2 Gyjtrs Business Overview
  28. 7.5.3 Gyjtrs Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Gyjtrs Neuromyelitis Optica Therapy Product Portfolio
  30. 7.5.5 Gyjtrs Recent Developments
  31. 7.6 Intas
  32. 7.6.1 Intas Company Information
  33. 7.6.2 Intas Business Overview
  34. 7.6.3 Intas Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Intas Neuromyelitis Optica Therapy Product Portfolio
  36. 7.6.5 Intas Recent Developments
  37. 7.7 NANG KUANG
  38. 7.7.1 NANG KUANG Company Information
  39. 7.7.2 NANG KUANG Business Overview
  40. 7.7.3 NANG KUANG Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 NANG KUANG Neuromyelitis Optica Therapy Product Portfolio
  42. 7.7.5 NANG KUANG Recent Developments
  43. 7.8 Octapharma
  44. 7.8.1 Octapharma Company Information
  45. 7.8.2 Octapharma Business Overview
  46. 7.8.3 Octapharma Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Octapharma Neuromyelitis Optica Therapy Product Portfolio
  48. 7.8.5 Octapharma Recent Developments
  49. 7.9 Tianjin Kingyork
  50. 7.9.1 Tianjin Kingyork Company Information
  51. 7.9.2 Tianjin Kingyork Business Overview
  52. 7.9.3 Tianjin Kingyork Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Tianjin Kingyork Neuromyelitis Optica Therapy Product Portfolio
  54. 7.9.5 Tianjin Kingyork Recent Developments
  55. 7.10 Baxter
  56. 7.10.1 Baxter Company Information
  57. 7.10.2 Baxter Business Overview
  58. 7.10.3 Baxter Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Baxter Neuromyelitis Optica Therapy Product Portfolio
  60. 7.10.5 Baxter Recent Developments
  61. 7.11 Pfizer
  62. 7.11.1 Pfizer Company Information
  63. 7.11.2 Pfizer Business Overview
  64. 7.11.3 Pfizer Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Pfizer Neuromyelitis Optica Therapy Product Portfolio
  66. 7.11.5 Pfizer Recent Developments
  67. 7.12 Sandoz
  68. 7.12.1 Sandoz Company Information
  69. 7.12.2 Sandoz Business Overview
  70. 7.12.3 Sandoz Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sandoz Neuromyelitis Optica Therapy Product Portfolio
  72. 7.12.5 Sandoz Recent Developments
  73. 7.13 Teva
  74. 7.13.1 Teva Company Information
  75. 7.13.2 Teva Business Overview
  76. 7.13.3 Teva Neuromyelitis Optica Therapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Teva Neuromyelitis Optica Therapy Product Portfolio
  78. 7.13.5 Teva Recent Developments
8 North America
  1. 8.1 North America Neuromyelitis Optica Therapy Revenue (2021-2032)
  2. 8.2 North America Neuromyelitis Optica Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Neuromyelitis Optica Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Neuromyelitis Optica Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Neuromyelitis Optica Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Neuromyelitis Optica Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Neuromyelitis Optica Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Neuromyelitis Optica Therapy Revenue by Country
  11. 8.6.1 North America Neuromyelitis Optica Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neuromyelitis Optica Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Neuromyelitis Optica Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Neuromyelitis Optica Therapy Revenue (2021-2032)
  2. 9.2 Europe Neuromyelitis Optica Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neuromyelitis Optica Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neuromyelitis Optica Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neuromyelitis Optica Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neuromyelitis Optica Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neuromyelitis Optica Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neuromyelitis Optica Therapy Revenue by Country
  11. 9.6.1 Europe Neuromyelitis Optica Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neuromyelitis Optica Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neuromyelitis Optica Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Neuromyelitis Optica Therapy Revenue (2021-2032)
  2. 10.2 China Neuromyelitis Optica Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Neuromyelitis Optica Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Neuromyelitis Optica Therapy Revenue by Type (2027-2032)
  5. 10.3 China Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Neuromyelitis Optica Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Neuromyelitis Optica Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Neuromyelitis Optica Therapy Revenue by Application (2027-2032)
  9. 10.5 China Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuromyelitis Optica Therapy Revenue (2021-2032)
  2. 11.2 Asia Neuromyelitis Optica Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neuromyelitis Optica Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neuromyelitis Optica Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neuromyelitis Optica Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neuromyelitis Optica Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neuromyelitis Optica Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neuromyelitis Optica Therapy Revenue by Country
  11. 11.6.1 Asia Neuromyelitis Optica Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neuromyelitis Optica Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neuromyelitis Optica Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuromyelitis Optica Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Neuromyelitis Optica Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neuromyelitis Optica Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neuromyelitis Optica Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neuromyelitis Optica Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neuromyelitis Optica Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neuromyelitis Optica Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neuromyelitis Optica Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neuromyelitis Optica Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neuromyelitis Optica Therapy Revenue by Country
  11. 12.6.1 SAMEA Neuromyelitis Optica Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neuromyelitis Optica Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neuromyelitis Optica Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst